Everolimus and Lutathera for refractory meningioma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two drugs (everolimus and 177Lu-DOTATATE) for people with grade 2 or 3 meningioma that has grown despite prior treatments. It aims to see if this combination can slow or stop tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 79 years old
- Your meningioma must be grade 2 or 3 and has grown or caused symptoms despite prior surgery or radiation
- A recent PET scan must show your tumor expresses somatostatin receptors (a protein that helps the drug target the tumor)
- You must have had a brain MRI and a specific PET scan (68Ga-DOTATOC) within the last 2 months
- You cannot be pregnant or breastfeeding and must use effective birth control if you could become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a targeted radioactive medicine (Lu-177-satoreotide) for meningiomas that keep coming back or keep growing. It works only if tumor imaging shows the tumor has the right “target” signal, and it aims to see how well it can control the disease and how safe it is.
This trial tests if Lutathera, a radioactive drug that targets certain tumors, can help children and young adults with high-grade brain tumors or meningiomas that have come back or are growing. It aims to see if the treatment is safe and works.
This trial tests a combination of two investigational drugs for people with NF2-related tumors. The drugs target specific pathways to help shrink or slow growth of vestibular schwannomas and meningiomas.
This Phase 2 study tests Lutathera to treat meningioma that cannot be safely removed with surgery and is still growing after radiation. It uses a special scan to make sure the tumor has the right target, and aims to improve tumor control and safety.
This study tests a radioactive drug, lutetium-177 DOTATATE, against standard care for people whose meningioma has grown despite earlier surgery and radiation. The treatment targets a protein on tumor cells, which may slow or stop growth.
This trial tests a radioactive drug called 177Lu-DOTATATE for people with recurrent meningioma (a type of brain tumor) that has grown after surgery and radiation. The drug targets a protein on the tumor cells and delivers radiation directly to them.
Hear when a new Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.